Given the favorable safety profile and promising efficacy, WX-0593 may potentially provide a new therapeutic option for Chinese advanced NSCLC patients with ALK or ROS1 rearrangement, thus contributing to reducing the treatment costs and increasing drug accessibility. The gene discussed is ALK; the disease is non-small cell lung carcinoma.